Table 1 Anti-diabetic activity of PSTi8 on the basis of AUC in different animal models during GTT, ITT and PTT after acute and chronic treatment.
Phenotyping screening | Glucose tolerance test | Insulin tolerance test | Pyruvate tolerance test | ||||||
|---|---|---|---|---|---|---|---|---|---|
Treatment | saline | Acute PSTi8 | Chronic PSTi8 | saline | Acute PSTi8 | Chronic PSTi8 | Saline | Acute PSTi8 | Chronic PSTi8 |
Mice model | |||||||||
HFD (N = 6) | 69980 ± 3317 mg/dL × min | 56611 ± 2847 mg/dL × min, **α | 30083 ± 3353 mg/dL × min, ***β, ***δ | 29109 ± 820 mg/dL × min | 25839 ± 546 mg/dL × min, **α | (16410 ± 1215 mg/dL × min, **β, ***δ | 58582 ± 2019 mg/dL × min | 51131 ± 612 mg/dL × min, *α | 43481 ± 1856 mg/dL × min, **β, **δ |
HFrD (N = 6) | 62870 ± 822 mg/dL × min | 38997 ± 581 mg/dL × min,***α | 31023 ± 875 mg/dL × min, ***β, ***δ | 23605 ± 1466 mg/dL × min | (18413 ± 480 mg/dL × min, **α | 14608 ± 392 mg/dL × min, ***β, ***δ | 38767 ± 3020 mg/dL × min | 31142 ± 5926 mg/dL × min, *α | 25323.8 ± 1492.98 mg/dL × min, *β, **δ |
db/db (N = 6) | 59271 ± 1750 mg/dL × min | 38967 ± 3204 mg/dL × min, ***α | 29356 ± 2101 mg/dL × min, *β, ***δ | 29307 ± 2394 mg/dL × min | 19983 ± 1004 mg/dL × min, *α | 13832 ± 993 mg/dL × min, **β, ***δ | 42401 ± 8387 mg/dL × min | 21360 ± 1008 mg/dL × min, *α | 17025 ± 1119 mg/dL × min, **β, *δ |
